A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Required: EGFR ex20ins mutation

Participants with EGFR ex20ins mutation.

Must have received: platinum-based chemotherapy — advanced disease

platinum containing ... systemic therapy

Must have received: immunotherapy — advanced disease

immunotherapy containing systemic therapy

Cannot have received: monoclonal antibody targeting EGFR

Any monoclonal antibodies targeting EGFR/HER2/VEGFR within 4 weeks

Cannot have received: monoclonal antibody targeting HER2

Any monoclonal antibodies targeting EGFR/HER2/VEGFR within 4 weeks

Cannot have received: monoclonal antibody targeting VEGFR

Any monoclonal antibodies targeting EGFR/HER2/VEGFR within 4 weeks

Cannot have received: cytotoxic chemotherapy

Any cytotoxic drugs or other anticancer drugs from a previous treatment regimen within 14 days

Cannot have received: anticancer herbal medicine

Any anticancer herbal medicine within 7 days

Cannot have received: anti-EGFR TKI

Exception: for the EGFR ex20ins mutation

Any anti-EGFR TKI for the EGFR ex20ins mutation

Cannot have received: third-generation anti-EGFR TKI

Exception: during the treatment having achieved a best overall response of the partial response or complete response

Any third-generation anti-EGFR TKI during the treatment having achieved a best overall response of the partial response or complete response